annual EBIT:
$2.53B+$1.33B(+111.74%)Summary
- As of today (May 29, 2025), TAK annual earnings before interest & taxes is $2.53 billion, with the most recent change of +$1.33 billion (+111.74%) on March 1, 2025.
- During the last 3 years, TAK annual EBIT has fallen by -$1.26 billion (-33.21%).
- TAK annual EBIT is now -52.75% below its all-time high of $5.35 billion, reached on March 31, 2007.
Performance
TAK EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
-$373.64M-$753.92M(-198.26%)Summary
- As of today (May 29, 2025), TAK quarterly earnings before interest & taxes is -$373.64 million, with the most recent change of -$753.92 million (-198.26%) on March 1, 2025.
- Over the past year, TAK quarterly EBIT has increased by +$304.52 million (+44.90%).
- TAK quarterly EBIT is now -113.91% below its all-time high of $2.69 billion, reached on June 30, 2021.
Performance
TAK quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
$2.53B+$304.52M(+13.68%)Summary
- As of today (May 29, 2025), TAK TTM earnings before interest & taxes is $2.53 billion, with the most recent change of +$304.52 million (+13.68%) on March 1, 2025.
- Over the past year, TAK TTM EBIT has increased by +$1.19 billion (+88.41%).
- TAK TTM EBIT is now -58.45% below its all-time high of $6.09 billion, reached on September 30, 2021.
Performance
TAK TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
TAK EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +111.7% | +44.9% | +88.4% |
| 3 y3 years | -33.2% | +42.2% | -36.8% |
| 5 y5 years | +211.4% | +55.6% | +155.1% |
TAK EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -33.2% | +111.7% | -123.0% | +44.9% | -38.3% | +113.7% |
| 5 y | 5-year | -46.1% | +211.4% | -113.9% | +55.6% | -58.5% | +155.1% |
| alltime | all time | -52.8% | +345.7% | -113.9% | +86.4% | -58.5% | +305.8% |
TAK EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | $2.53B(+111.7%) | -$373.64M(-198.3%) | $2.53B(+13.7%) |
| Dec 2024 | - | $380.27M(-69.9%) | $2.23B(-17.9%) |
| Sep 2024 | - | $1.26B(+0.4%) | $2.71B(+129.0%) |
| Jun 2024 | - | $1.26B(-285.7%) | $1.18B(-11.8%) |
| Mar 2024 | $1.19B(-67.2%) | -$678.16M(-178.3%) | $1.34B(-41.9%) |
| Dec 2023 | - | $865.73M(-429.4%) | $2.31B(-16.6%) |
| Sep 2023 | - | -$262.78M(-118.5%) | $2.77B(-28.8%) |
| Jun 2023 | - | $1.42B(+391.4%) | $3.89B(-5.1%) |
| Mar 2023 | $3.64B(-3.7%) | $288.62M(-78.2%) | $4.10B(+29.6%) |
| Dec 2022 | - | $1.33B(+54.7%) | $3.16B(+9.7%) |
| Sep 2022 | - | $856.73M(-47.4%) | $2.88B(-2.1%) |
| Jun 2022 | - | $1.63B(-351.7%) | $2.95B(-26.4%) |
| Mar 2022 | $3.79B(-19.3%) | -$646.91M(-161.9%) | $4.00B(-27.0%) |
| Dec 2021 | - | $1.05B(+13.8%) | $5.48B(-9.9%) |
| Sep 2021 | - | $918.73M(-65.8%) | $6.09B(+6.3%) |
| Jun 2021 | - | $2.69B(+222.2%) | $5.73B(+22.2%) |
| Mar 2021 | $4.69B(+477.4%) | $833.68M(-49.5%) | $4.69B(+55.6%) |
| Dec 2020 | - | $1.65B(+196.3%) | $3.01B(+51.2%) |
| Sep 2020 | - | $557.28M(-66.1%) | $1.99B(-6.3%) |
| Jun 2020 | - | $1.65B(-295.5%) | $2.13B(+114.4%) |
| Mar 2020 | $812.03M(-48.8%) | -$842.09M(-233.5%) | $992.02M(-14.6%) |
| Dec 2019 | - | $630.68M(-8.9%) | $1.16B(+0.9%) |
| Sep 2019 | - | $692.29M(+35.4%) | $1.15B(+0.9%) |
| Jun 2019 | - | $511.14M(-175.9%) | $1.14B(-29.9%) |
| Mar 2019 | $1.59B(-22.7%) | -$673.13M(-208.6%) | $1.62B(+6.3%) |
| Dec 2018 | - | $619.78M(-9.1%) | $1.53B(+5.1%) |
| Sep 2018 | - | $682.08M(-31.5%) | $1.45B(+27.6%) |
| Jun 2018 | - | $996.22M(-229.5%) | $1.14B(-43.5%) |
| Mar 2018 | $2.05B(+47.0%) | -$769.48M(-240.9%) | $2.02B(-5.2%) |
| Dec 2017 | - | $546.13M(+48.6%) | $2.13B(-0.0%) |
| Sep 2017 | - | $367.53M(-80.4%) | $2.13B(+13.9%) |
| Jun 2017 | - | $1.87B(-384.4%) | $1.87B(+30.6%) |
| Mar 2017 | $1.40B(+9.8%) | -$658.92M(-220.5%) | $1.43B(-20.8%) |
| Dec 2016 | - | $546.97M(+404.8%) | $1.81B(+2.6%) |
| Sep 2016 | - | $108.36M(-92.5%) | $1.76B(-20.8%) |
| Jun 2016 | - | $1.44B(-605.6%) | $2.22B(+79.7%) |
| Mar 2016 | $1.27B | -$283.93M(-156.7%) | $1.24B(-200.7%) |
| Dec 2015 | - | $500.74M(-12.4%) | -$1.23B(+27.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | $571.59M(+27.2%) | -$966.10M(-0.1%) |
| Jun 2015 | - | $449.45M(-116.3%) | -$967.28M(+29.8%) |
| Mar 2015 | -$1.03B(-154.4%) | -$2.75B(-460.0%) | -$745.42M(-143.0%) |
| Dec 2014 | - | $764.42M(+34.0%) | $1.73B(-4.5%) |
| Sep 2014 | - | $570.41M(-15.0%) | $1.82B(-7.8%) |
| Jun 2014 | - | $671.31M(-346.5%) | $1.97B(+2.8%) |
| Mar 2014 | $1.89B(+1.9%) | -$272.36M(-132.2%) | $1.92B(-5.6%) |
| Dec 2013 | - | $846.43M(+17.0%) | $2.03B(+24.5%) |
| Sep 2013 | - | $723.18M(+16.9%) | $1.63B(+1.2%) |
| Jun 2013 | - | $618.49M(-487.3%) | $1.61B(-17.3%) |
| Mar 2013 | $1.86B(-42.4%) | -$159.71M(-135.7%) | $1.95B(+12.3%) |
| Dec 2012 | - | $447.83M(-36.4%) | $1.73B(-22.5%) |
| Sep 2012 | - | $703.99M(-26.2%) | $2.24B(-17.1%) |
| Jun 2012 | - | $954.50M(-356.2%) | $2.70B(-15.9%) |
| Mar 2012 | $3.22B(-25.6%) | -$372.52M(-139.1%) | $3.21B(-20.0%) |
| Dec 2011 | - | $952.55M(-18.3%) | $4.02B(-8.9%) |
| Sep 2011 | - | $1.17B(-20.4%) | $4.41B(-5.4%) |
| Jun 2011 | - | $1.47B(+239.5%) | $4.66B(+7.7%) |
| Mar 2011 | $4.33B(-3.7%) | $431.50M(-68.0%) | $4.33B(-1.9%) |
| Dec 2010 | - | $1.35B(-5.1%) | $4.41B(+1.6%) |
| Sep 2010 | - | $1.42B(+25.4%) | $4.34B(+3.8%) |
| Jun 2010 | - | $1.13B(+119.3%) | $4.18B(-6.4%) |
| Mar 2010 | $4.50B(+11.7%) | $516.02M(-59.6%) | $4.47B(-5.2%) |
| Dec 2009 | - | $1.28B(+1.3%) | $4.72B(-6.1%) |
| Sep 2009 | - | $1.26B(-11.0%) | $5.02B(+5.0%) |
| Jun 2009 | - | $1.42B(+85.6%) | $4.78B(+42.1%) |
| Mar 2009 | $4.02B(-20.5%) | $762.82M(-51.8%) | $3.37B(+29.3%) |
| Dec 2008 | - | $1.58B(+55.4%) | $2.60B(+155.4%) |
| Sep 2008 | - | $1.02B | $1.02B |
| Mar 2008 | $5.06B(-5.4%) | - | - |
| Mar 2007 | $5.35B(+16.7%) | - | - |
| Mar 2006 | $4.58B(+11.4%) | - | - |
| Mar 2005 | $4.11B(+3.8%) | - | - |
| Mar 2004 | $3.96B(+11.5%) | - | - |
| Mar 2003 | $3.55B(+18.5%) | - | - |
| Mar 2002 | $3.00B(+25.2%) | - | - |
| Mar 2001 | $2.39B(+30.1%) | - | - |
| Mar 2000 | $1.84B | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual earnings before interest & taxes?
- What is the all time high annual EBIT for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual EBIT year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly EBIT year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM EBIT year-on-year change?
What is Takeda Pharmaceutical Company Limited annual earnings before interest & taxes?
The current annual EBIT of TAK is $2.53B
What is the all time high annual EBIT for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual earnings before interest & taxes is $5.35B
What is Takeda Pharmaceutical Company Limited annual EBIT year-on-year change?
Over the past year, TAK annual earnings before interest & taxes has changed by +$1.33B (+111.74%)
What is Takeda Pharmaceutical Company Limited quarterly earnings before interest & taxes?
The current quarterly EBIT of TAK is -$373.64M
What is the all time high quarterly EBIT for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly earnings before interest & taxes is $2.69B
What is Takeda Pharmaceutical Company Limited quarterly EBIT year-on-year change?
Over the past year, TAK quarterly earnings before interest & taxes has changed by +$304.52M (+44.90%)
What is Takeda Pharmaceutical Company Limited TTM earnings before interest & taxes?
The current TTM EBIT of TAK is $2.53B
What is the all time high TTM EBIT for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM earnings before interest & taxes is $6.09B
What is Takeda Pharmaceutical Company Limited TTM EBIT year-on-year change?
Over the past year, TAK TTM earnings before interest & taxes has changed by +$1.19B (+88.41%)